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ABSTRACT 
   Objective      To assess if a coding variant in the gene 
encoding transient receptor potential cation channel, 
subfamily V, member 1 (  TRPV1  ) is associated with 
genetic risk of painful knee osteoarthritis (OA).   
  Methods    The  Ile585Val   TRPV1   variant encoded by 
rs8065080 was genotyped in 3270 cases of symptomatic 
knee OA, 1098 cases of asymptomatic knee OA and 
3852 controls from seven cohorts from the UK, the USA 
and Australia. The genetic association between the 
low-pain genotype Ile–Ile and risk of symptomatic and 
asymptomatic knee OA was assessed.   
  Results    The   TRPV1   585 Ile–Ile genotype, reported to 
be associated with lower thermal pain sensitivity, was 
associated with a lower risk of symptomatic knee OA 
in a comparison of symptomatic cases with healthy 
controls, with an odds ratio (OR) of 0.75 (95% CI 0.64 
to 0.88; p=0.00039 by meta-analysis) after adjustment 
for age, sex and body mass index. No difference was 
seen between asymptomatic OA cases and controls 
(OR=1.02, 95% CI 0.82 to 1.27 p=0.86) but the Ile–Ile 
genotype was associated with lower risk of symptomatic 
versus asymptomatic knee OA adjusting for covariates 
and radiographic severity (OR=0.73, 95% CI 0.57 to 0.94 
p=0.0136).   TRPV1   expression in articular cartilage was 
increased by inﬂ  ammatory cytokines (tumour necrosis 
factor α and interleukin 1). However, there were no 
differences in   TRPV1   expression in healthy and arthritic 
synovial  tissue.   
  Conclusions      A genotype involved in lower peripheral 
pain sensitivity is signiﬁ  cantly associated with a 
decreased risk of painful knee OA. This indicates a role for 
the pro-nociceptive gene   TRPV1   in genetic susceptibility 
to symptomatic knee OA, which may also be inﬂ  uenced 
by a role for this molecule in cartilage function.           
  INTRODUCTION 
  Osteoarthritis (OA) is the leading cause of physi-
cal disability in industrialised nations with severely 
impaired quality of life due to pain and loss of 
joint functioning.  1   Pain is the major symptom of 
knee OA, and pain and disability in the presence 
of radiographic knee OA are the primary indica-
tions for total knee replacement. A patient who 
has severe knee pain and extensive radiographic 
evidence of OA is thought to have an ‘obvi-
ous’ explanation for the pain.  2   Within the same 
patient, knee pain has been shown to be higher in 
the knee with greater x-ray damage.  3   Yet, a con-
siderable number of individuals have advanced 
radiographic OA (Kellgren–Lawrence (K/L) scores 
≥3) in   asymptomatic joints.  2     3   For example, in 
the Framingham study only 19% of people with 
K/  L=2 and 40% of those with K/L≥3 had knee pain 
on most days in the previous month,  4   and in the 
Baltimore longitudinal study only 56% of cases 
with K/L≥3 had current pain.  5   
  Thus, although a correlation between OA joint 
damage and pain can be found, there is often dis-
cordance between the degree of structural change 
and the severity of pain, so disease severity 
deﬁ   ned exclusively by structural degeneration is 
inadequate. 
  One possible factor inﬂ  uencing pain severity in 
the presence of joint damage is a patient’s indi-
vidual sensitivity to pain, which has been shown 
to be strongly inﬂ  uenced by genetics.  6   The tran-
sient receptor potential cation channel, subfamily 
V, member 1 (  TRPV1  ) is a thermosensitive chan-
nel present in a subpopulation of primary afferent 
sensory neurons and activated by noxious heat.  7     8   
Notably, inﬂ  ammatory stimuli sensitise   TRPV1  , a 
process that contributes to pain hypersensitivity in 
the context of tissue injury (see references in the 
article by Huang   et al     9  ). Preclinical studies have 
provided mounting evidence for a contribution of 
  TRPV1   to pain in animal models of OA. Indeed, 
expression of   TRPV1   is upregulated in the cell bod-
ies of primary afferent ﬁ  bres innervating the joint in 
the monosodium iodoacetate model of OA pain  10   
and systemic administration of   TRPV1   antagonists 
blocks hyperalgesia and mechanical allodynia in 
these models.  11   Expression of   TRPV1,   however, is 
not limited to neural cells but is also found in other 
cells in the joint, including chondrocytes, osteo-
clasts, osteoblasts and synovial ﬁ  broblasts,  12    –    14   
and thus the potential role of   TRPV1   in OA is not 
  limited to pain sensation. 
  An amino acid variant, Ile585Val encoded by 
rs8065080, in the   TRPV1   gene has been reported 
to be associated with thermal pain sensitivity,  15     16   
with the Ile–Ile genotype corresponding to lower 
sensitivity to cold pain. The aim of this study was 
to determine whether there is a role for this geno-
type in risk of symptomatic knee OA compared 
both with healthy non-OA controls and with 
  people with asymptomatic radiographic knee OA. 
  The expression of   TRPV1   in human cartilage and 
synovium from patients undergoing arthroplasty as 
well as normal mouse cartilage has also been quan-
tiﬁ  ed to provide evidence that   TRPV1   is present 
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in joint tissues and may play a role in the process of cartilage 
breakdown leading to a damaged joint.   
  SUBJECTS  AND  METHODS 
  Data from ﬁ  ve study cohorts from the UK, a study cohort in the 
USA and a study cohort from Australia were used. The study 
protocols for each cohort were approved by the local research 
ethics committees or institutional review board and all study 
participants gave fully informed consent to participate in genetic 
studies. For consistency between cohorts for the current study 
the radiographic deﬁ  nition of knee OA was a K/L grade ≥2  17   at 
the tibiofemoral compartment at one or both knees. Details on 
each of the study cohorts, recruitment, x-ray ﬁ  ndings and pain 
assessment are included in the online supplementary section 
and the descriptive characteristics are shown in   table 1  . Because 
the Nottingham Case–Control Study did not have any asymp-
tomatic subjects and the Hertfordshire Cohort Study had very 
few symptomatic subjects and these two UK study cohorts had 
similar age ranges, data for these two studies have been pooled 
for all analyses.   
  Laboratory  methods 
  Genotyping 
  Genomic DNA was extracted from peripheral blood and DNA 
from the Genetics of Osteoarthrits and Lifestyle (GOAL) cohort 
was further whole genome ampliﬁ  ed using standard protocols. 
Genotyping of the rs8065080 single nucleotide polymorphism 
(SNP) was carried out by Kbioscience Ltd, Hertfordshire, UK. 
SNPs were genotyped using the KASPar chemistry, a competi-
tive allele-speciﬁ  c PCR SNP genotyping system. The polymor-
phism was in Hardy–Weinberg equilibrium in controls (p>0.05) 
in all cohorts. Fifty-two samples were genotyped in duplicate 
and the concordance rate was 100%.     
  Gene  expression  experiments 
  All procedures to obtain and work with human samples 
were approved by the ethical committee for clinical research 
at KU Leuven and patient informed consent was obtained. 
The informed consents preclude the analysis of the tissues 
for genomic analysis. Cartilage explants were obtained from 
patients undergoing total knee prosthesis surgery in the depart-
ment of orthopaedics, University Hospitals Leuven. Pieces of 
cartilage were selected from visually healthy zones of the speci-
mens. Cartilage explants from four different donors were used 
in triplicate cultures. Pieces were cultured in vitro in Dulbecco’s 
modiﬁ  ed Eagle’s medium (DMEM) (Gibco, Carlsbad, California, 
USA) for 10 days in the presence or absence of interleukin (IL) 
1 and tumour necrosis factor α (TNFα) 10 ng/ml (Peprotech, 
Rocky Hill New Jersey, USA)  . Synovial biopsy specimens were 
obtained from patients undergoing arthroscopy of the knee for 
meniscal and cartilage injury in the department of orthopaedics 
or from patients with chronic arthritis undergoing diagnostic nee-
dle arthroscopy (one rheumatoid arthritis, two psoriatic arthri-
tis) in the department of rheumatology, University Hospitals 
Leuven. Histological or ﬂ  ow cytometric analysis revealed that 
the control synovia had no signs of chronic inﬂ  ammation. 
Synovial ﬁ  broblasts were   collected and cultured as described 
by Lories   et al  .  18   Primary cells were cultured in DMEM/10% 
fetal bovine serum in the presence or absence of TNFα (0.1–10 
ng/ml) and human IL-1β (0.1–10 ng/  ml) for 2–24 h. 
  Expression levels of   TRPV1   were determined by quantitative 
real-time PCR using commercially available Taqman primer-
probes sets (Applied Biosystems) for   TRPV1   and housekeeping 
gene β-actin. Data were analysed with the ΔCt method relative 
to housekeeping gene β-actin for the synovial tissue samples 
and with a standardised method for independent biological rep-
licates based on ΔΔCt with log transformation, mean centring, 
 Table  1        Descriptive characteristics of study subjects   
 
 Cohort  name 
 Genetics  of 
Osteoarthritis 
and Lifestyle 
 Hertfordshire 
Cohort Study 
 Nottingham 
Case-Control 
Study   Chingford  Study   TwinsUK  Study 
 Clearwater 
Osteoarthritis 
Study 
 Tasmanian 
Older Adult 
Cohort 
Cohort acronym GOAL HCS Nott Chingford TwinsUK COS TASOAC
Country of origin UK UK UK UK UK USA Australia
Knee OA
Symptomatic n=1199 n=86 n=1703 n=68 n=45 n=83 n=86
Age (years), mean (SD) 68.4 (7.2) 65.3 (2.8) 68.7 (8.9) 65.7 (5.8) 57.5 (7.2) 65.6 (8.3) 65.0 (7.2)
Female (%) 46.9 44.3 55.3 100 100 66.7 58.50
BMI (kg/m  2  ), mean (SD) 31.2 (5.4) 29.7 (5.4) 29.7 (5.4) 26.7 (3.4) 27.9(4.5) 29.1 (5.1) 31.3 (6.3)
K/L≥3 (%) 89.7 38.6 80.8 44.1 29.0 32.9 42.6
TKR (%) 94.8 9.3 90.3 23.5 26.7 24 0
  TRPV1   585 Ile–Ile (%) 11.4 12.8 12.9 8.8 9.3 15.5 12.6
MAF (%) 35.1 37.2 36.9 38.2 31.4 33.8 35.1
Asymptomatic n=376 n=44 n=0 n=216 n=235 n=91 n=136
Age (years), mean (SD) 69.0 (6.7) 65.2 (6.4) N/A 65.7 (5.9) 58.1 (7.8) 64.0 (9.8) 65.8 (7.6)
Female (%) 43.9 31.8 N/A 100 100 54.6 43.80
BMI (kg/m  2  ), mean (SD) 28.9 (4.9) 28.4 (4.0) N/A 26.2 (4.4) 26.7 (4.9) 26.1 (4.7) 28.1 (4.3)
K/L≥3 (%) 49.5 15.9 N/A 26.4 34.0 21.7 24.8
TKR (%) 0 0 N/A 0 0 0 0
  TRPV1   585 Ile–Ile (%) 14.4 11.9 N/A 11.7 17.1 17.6 18.4
MAF (%) 38.2 40.4 N/A 37.4 40.2 43.5 43.4
Unaffected n=743 n=542 n=728 n=532 n=978 n=0 n=329
Age years mean (SD) 62.6 (8.4) 64.8 (2.7) 66.3 (7.4) 62.9 (5.7) 52.9 (7.2) N/A 61.8 (7.5)
Female (%) 49.9 50.1 57.4 100 100 N/A 47.9
BMI (kg/m  2  ) mean (SD) 27.1 (4.4) 26.2 (3.8) 26.6(3.9) 24.7 (3.6) 24.5 (4.0) N/A 27.4 (4.4)
  TRPV1   585 Ile–Ile (%) 15.5 15.6 16.1 13.6 15.0 N/A 16.20
MAF (%) 38.5 38.5 37.8 38.1 37.8   38.8
      BMI, body mass index; K/L, Kellgren–Lawrence; MAF, minor allele frequency; TKR, total knee replacement.     
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and autoscaling as proposed by Willems   et al    19   for the in vitro 
experiments.   
  Statistical  analysis 
  The association between the CC genotype at rs8065080 (Ile–Ile 
at   TRPV1   codon 585) and knee OA (symptomatic and asymp-
tomatic separately or together) versus controls was assessed by 
comparison of the frequency of the   TRPV1   585 Ile–Ile genotype 
in knee OA cases and controls in unadjusted analyses and using a 
logistic regression model to adjust for covariates. The ORs from 
all cohorts were meta-analysed using a ﬁ  xed-effects model. The 
natural logarithm of the odds ratio and its SE were estimated 
independently within each study adjusted for age, gender, body 
mass index (BMI) and in the case of symptomatic versus symp-
tomatic cases also for radiographic severity (the maximum for 
radiographic OA (ROA) cases, the presurgical grade for the 
index knee in total knee replacement cases). For the TwinsUK 
Cohort in addition the estimates were corrected for the relat-
edness between individuals using a mixed-effects model with 
a robust estimate of the SE for the β coefﬁ  cient calculated by 
clustering over twin pairs. 
  Meta-analyses of data from these different cohorts were per-
formed using R version 2.10.1 (the R Foundation for Statistical 
Computing   http://www.r-project.org/  ). Heterogeneity was 
evaluated with Q statistic and I  2  . Random-effects models were 
not used as no heterogeneity was seen for any of the analyses 
(I  2   <10%). Pooled analyses of all cohorts were also carried out, 
simply grouping all data in a single analysis.     
  RESULTS 
  The descriptive characteristics of the study cohorts including 
the Ile–Ile 585 genotype frequency and the number of control, 
symptomatic and asymptomatic knee OA cases available for 
each study are shown in   table 1  . 
  We tested, using a crude meta-analysis (ie, simply compar-
ing genotype frequencies), whether the Ile–Ile genotype was 
associated with knee OA, and found that the Ile–Ile geno-
type at codon position 585 of the TRPV1 protein was associ-
ated with lower risk of knee OA (  table 2  ). This association 
was stronger when only symptomatic knee OA cases were 
included (  table 2  ) A much more modest and not signiﬁ  cant 
difference was seen between asymptomatic OA cases and 
controls (  table 2  ) but a comparison between symptomatic 
and asymptomatic OA gave a statistically signiﬁ  cant result 
OR=0.76 (95% CI 0.59 to 0.99) p=0.0378 (  table 2  ).   We then 
carried out a pooled analysis combining all samples regardless 
of cohort of origin in a single analysis, but adjusting for cova-
riates and found results to be extremely similar to those from 
the meta-analysis (  table 2  ).  
  We further tested for association adjusting for age, sex and 
BMI in each of the study cohorts independently ﬁ  rst (  table 2  ) 
and meta-analysed them. We conﬁ  rmed the association with 
knee OA overall (  ﬁ  gure 1A  ), the stronger association between 
symptomatic OA versus controls (  ﬁ  gure 1B  ) and the lack of asso-
ciation between asymptomatic OA and controls (  ﬁ  gure 1C  ).      We 
also investigated whether there was a difference between 
asymptomatic and symptomatic knee OA cases adjusting for 
age, sex, BMI and radiographic severity and this difference 
achieved statistical signiﬁ  cance (  ﬁ  gure 1D  ) (OR=0.74, 95% CI 
0.57 to 0.97 p=0.014).    
  Gene  expression 
  Gavenis   et al   demonstrated that   TRPV1   is expressed in articular 
chondrocytes, but expression decreases with dedifferentiation 
of the cells upon in vitro culture and passaging.  12     Here we eval-
uated the effects of the proinﬂ  ammatory and cartilage destruc-
tive cytokines IL-1 and TNFα on gene expression of   TRPV1   in 
articular cartilage explants obtained from patients with end-
stage knee OA, undergoing prosthesis surgery. Exposure to IL-1 
and TNFα in vitro signiﬁ  cantly upregulated   TRPV1   expression 
in challenged cartilage (average relative expression 3.34 (95% 
CI 2.55 to 4.37) versus 1 (95% CI 0.68 to 1.48) (n=4) (  ﬁ  gure 2A  ). 
Expression of   TRPV1   in synovial ﬁ  broblasts from patients with 
rheumatoid arthritis and OA  14   and in the synoviocyte cell line 
SW982  20   has been shown to be upregulated by TNFα. Despite 
this, we found no difference in the expression of   TRPV1   in syn-
ovial tissue biopsy specimens between patients without, and 
those with, inﬂ  ammatory arthritis, suggesting that proinﬂ  am-
matory cytokines have differential effects on synovial tissue 
and articular cartilage (average relative expression compared 
with β-actin (×1000) 2.48 (95% CI −1.80 to 6.00)) versus 3.47 
(95% CI −1.37 to 8.29)) (n=3 per group) (  ﬁ  gure 2B  ). Given the 
difference between our observations in articular cartilage and 
synovial tissue, we further examined the regulation of   TRPV1   
expression in normal human synovial ﬁ  broblast in the pres-
ence or absence of IL-1 and TNFα. In contrast to the results 
reported for SW982 cells, we found no upregulation or down-
regulation of   TRPV1   in synovial ﬁ  broblasts treated with IL-1 
or TNFα for 30 min to 24 h (dose range 0.1–10 ng/ml (n=3) 
(data not shown).       
 Table  2     Association  between  the   TRPV1   585 Ile–Ile genotype and symptomatic or asymptomatic knee osteoarthritis (OA) in a crude meta-analysis 
and in pooled analysis   
 Groups  compared   Sample  size 
 Summary  OR 
(95% CI) (crude 
Mantel–Haenzsel) 
 p  Value 
meta-analysis 
 Heterogeneity  I   2   
 p(Cochran’s  Q) 
 Pooled  analysis 
OR (95% CI) 
  p Value pooled 
analysis 
Any knee OA versus 
controls
4368 cases, 
3852 controls
0.83 (0.73 to 0.95) 0.0073   I    2    =0% p(Q)<0.39 0.84 (0.72 to 0.98)  *  <0.0277  * 
Symptomatic knee OA 
versus controls
3270 cases, 
3852 controls
0.74 (0.64 to 0.87) 0.00022   I    2    =0% p(Q)<0.66 0.76 (0.64 to 0.92)  *  <0.0042  * 
Asymptomatic knee OA 
versus controls
1098 cases, 
3852 controls
0.99 (0.81 to 1.22) 0.93   I    2    =0% p(Q)<0.67 1.01 (0.78 to 1.31)  *  <0.92  * 
Symptomatic versus 
asymptomatic knee OA
3270 symptomatic 
cases, 1098 
asymptomatic cases
0.76 (0.59 to 0.99) 0.0378   I    2    =0% p(Q)<0.87 0.74 (0.55 to 0.99)   †  <0.0417  † 
      ORs refer to the risk of individuals carrying the   TRPV1   585 Ile–Ile compared with Val–Ile and Val–Val individuals.   
    *    Adjusted for age, sex and body mass index (BMI).   
  †    Adjusted for age, sex, BMI and Kellgren–Lawrence grade.   
  ‡    All estimates are also adjusted for relatedness between twins.     
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  DISCUSSION 
  In this study we report for the ﬁ   rst time an association 
between the   TRPV1   gene and risk of symptomatic knee OA. 
We found a signiﬁ  cant association between an amino acid 
variant in the TRPV1 molecule, which previously had been 
implicated in pain sensitivity, with the risk of symptomatic 
but not asymptomatic radiographic knee OA. The observa-
tion that the genotype implicated in lower pain sensitivity is 
signiﬁ  cantly associated with a lower risk of painful OA agrees 
with our initial hypothesis. After adjustment for confound-
ing variables (age, sex, BMI and radiographic severity) the 
difference between symptomatic and asymptomatic OA also 
achieves statistical signiﬁ  cance, further supporting our initial 
hypothesis. 
  We note that there are some study limitations. We only 
investigated the role of a single variant in the   TRPV1   gene and 
other SNPs in   TRPV1   may show a stronger association, which 
may be identiﬁ  ed by ﬁ  ner mapping of this gene. Moreover, our 
data apply only to subjects of European descent. Differences in 
the strength or even the presence of genetic associations have 
been reported between Asian and European patients (eg, Valdes 
  et al    21  ), therefore it is possible that this variant may not be 
  associated in other ethnic groups. 
  It is well recognised that there is an important genetic 
  contribution to the development of OA, with heritability esti-
mates in the order of 40–60% for knee, hip and hand OA.  22   
However, most studies investigating genetic associations with 
OA have focused on structural change in joint tissues rather 
than the clinical presentation with pain and disability once OA 
changes are established. Our ﬁ  nding that the association with 
the   TRPV1   gene is signiﬁ  cant only with symptomatic OA sug-
gests that consideration of the pain component of OA may aid 
discovery of stronger or more consistent genetic associations 
with OA. 
  Patients seek medical help for symptoms and the main indi-
cation for knee arthroplasty, the most effective treatment for 
severe knee OA, is pain rather than the degree of structural ROA. 
It is therefore essential to understand the relationship between 
radiographic changes and pain in OA. Although there is a statis-
tically signiﬁ  cant association between knee ROA and pain, it has 
been reported that <56% of subjects with moderate to severe 
knee ROA (K/L≥3) actually experience regular pain.  2    –    5   A US 
study analysed patients with frequent pain in only one knee, but 
who had bilateral radiographs and found that although increas-
ing radiographic severity was signiﬁ  cantly associated with knee 
pain, 46% of participants had the same radiographic grade in 
 Figure  1     Forest plot showing study speciﬁ  c estimates for the association between the Ile–Ile   TRPV1   585 genotype and (A) knee osteoarthritis 
(OA; regardless of symptoms) versus controls; (B) symptomatic knee OA versus controls; (C) asymptomatic knee OA versus controls; 
(D) symptomatic versus asymptomatic knee OA.   *  OR estimates are adjusted for age sex and body mass index (BMI); †OR estimates are adjusted 
for age, sex, BMI and Kellgren–Lawrence grade; ‡OR estimates are adjusted for relatedness between twins. COS, Clearwater Osteoarthritis Study; 
GOAL, Genetics of Osteoarthritis and Lifestyle; HCS, Hertfordshire Cohort Study; TASOAC, Tasmanian Older Adult Cohort.       
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the symptomatic and asymptomatic knee and 10% had a worse 
radiographic grade in the asymptomatic knee.  23   Recently it has 
been shown that OA patients with high pre-arthroplasty pain 
and a low pain thresholds have higher persistent pain post-
TKR for OA, reﬂ  ecting the importance of an inherent predis-
position to higher pain sensitivity.  24   Genetic variation is one of 
the factors that can help explain the prevalence of pain in OA 
and this study adds new data in this direction. Understanding 
the molecular determinants of pain in knee OA has important 
clinical implications because current non-surgical treatments for 
knee OA offer limited pain relief with effect sizes of <0.5 for the 
most commonly used oral treatments when analysed in high-
quality trials.  25   New insights into the aetiopathogenesis of pain 
in patients with knee ROA may produce novel targets for new 
therapeutic interventions. 
  The genetic ﬁ  ndings reported in this paper are supported by 
preclinical studies, which indicate an important role of   TRPV1   
in pain processing and, speciﬁ  cally, in experimental models of 
OA pain (see ‘Introduction’). Indeed,   TRPV1   expression by the 
primary afferent sensory ﬁ  bre cell bodies innervating the joint 
is upregulated in a model of OA.  10   This altered expression of 
  TRPV1   is likely to have an impact upon both peripheral and spi-
nal  26   pain mechanisms in these models of OA pain. Since   TRPV1   
is expressed not only by primary afferent ﬁ  bres, but also in joint 
tissues, it is possible that the genetic variation in the   TRPV1   
gene may inﬂ  uence structural damage associated with OA. This 
notion is supported by evidence for a contribution of primary 
afferent nociceptors to the progression of structural changes 
within the joint. In that study, degeneration of primary afferent 
nociceptors innervating the joint after intra-articular injection of 
capsaicin signiﬁ  cantly decreased loss of bone volume and tra-
becular connectivity in a model of OA pain.  27   Such data sug-
gest that primary afferent nociceptors innervating the joint may 
also contribute to the progression of structural damage. Thus, 
in animal models of OA   TRPV1   has complex contributions to 
the structural changes and pain associated with OA, which may 
reﬂ  ect the multiple sites at which   TRPV1   is expressed within the 
joint and the pain pathways. 
  Our gene expression data in humans demonstrate that 
cytokine-induced stress to the articular cartilage increases expres-
sion of   TRPV1  . Interestingly, TNFα inﬂ  uences the phenotype 
and responses of primary afferent nociceptors—for example, 
TNFα increases the proportion of neurons that express   TRPV1  ,  28   
and therefore contributes to the generation and maintenance of 
inﬂ  ammatory joint pain. On this basis,   TRPV1   may inﬂ  uence 
both peripheral pain sensitivity and structural damage in knee 
OA. This is in agreement with recent clinical studies showing 
that the presence of knee pain is an independent predictor of 
longitudinal cartilage loss in patients with OA in addition to 
radiographic severity.  29   
  On the other hand, we failed to observe any differences 
between expression of   TRPV1   in normal and chronic inﬂ  am-
matory arthritis synovium. Earlier reports have demonstrated 
the expression of   TRPV1   in synovial ﬁ   broblasts. We could 
not conﬁ  rm upregulation by TNFα or IL-1 in our experimen-
tal system as was reported for a synovial cell line. However, 
in this cell line Kochucov   et al   also reported increased ther-
mal and chemical responses of TRPV channels in response to 
TNFα.  20   In addition, Hu and coworkers associated   TRPV1   with 
cell death in rat synoviocytes.  30   Of note, the synovial samples 
used in our experiements were not of OA origin and further 
research in OA synovium is needed to conﬁ  rm or disprove this 
lack of response to cytokines. Given that the cell bodies of the 
afferent ﬁ  bres are in the dorsal root ganglia and that cartilage 
is not normally innervated, the altered expression in the chon-
drocytes would appear to suggest a role for   TRPV1   in struc-
tural damage in OA. Further experiments investigating the role 
of   TRPV1   in pain in OA and in joint damage in OA will help 
clarify this issue. 
    TRPV1  , a member of the extended family of non-selective 
  cationic TRP channels, is important in pain sensation. At the time 
of writing there are compounds approved, or under consider-
ation, for regulatory approval which target this receptor to treat 
pain in large-joint OA.  31   Our data suggest that a study of genetic 
factors that speciﬁ  cally inﬂ  uence the risk of symptomatic OA 
may point to therapeutic pathways for the treatment of OA. 
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modiﬁ  ed Eagle’s medium/10% fetal bovine serum for 10 days with or without tumour necrosis factor α (TNFα) and interleukin 1 (IL-1; 10 ng/  ml) 
(triplicates).   TRPV1   expression was determined by real-time quantitative PCR and analysed using the delta-delta Ct method standardised for 
independent biological replicates. Data are expressed as mean and 95% CIs. The difference between the control conditions and the cytokine cultured 
conditions yielded a p<0.0001 in a Mann–Whitney U test. (B) Synovial biopsy specimens were analysed for expression of   TRPV1   by real-time 
qualitative PCR and data expressed as mean and 95% CIs using relative expression compared with housekeeping gene β-actin (n=3). The difference 
between the control conditions and the cytokine cultured conditions yielded a p<0.0.4 in a Mann–Whitney U test.         
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